Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Trading Update

29 Apr 2021 07:00

RNS Number : 9817W
Devro PLC
29 April 2021
 

Devro plc

 

Trading Update

 

Devro plc ("Devro" or the "Company"), one of the world's leading manufacturers of collagen products for the food industry, issues the following trading update for the period 1 January 2021 to the current date ahead of its Annual General Meeting today.

Current trading

Q1 2021 edible collagen volumes increased 4.6% compared to the prior year driven by continued good underlying momentum and execution of our growth initiatives. Emerging markets were up 15% led by strong growth in China, South East Asia and Latin America. Mature markets were flat on the prior year, an improvement on the trends seen in 2020. Japan and North America both delivered strong growth but this was offset by lower demand in the UK & Ireland which had benefitted from elevated retail volumes in March 2020 as the pandemic took hold.

Financial position

The Group delivered strong cashflows during Q1, ending the quarter with comparable levels of leverage to 2020 year-end, including the dividend payment made in January 2021.

The Group repaid the US$25 million private placement due on the 19 April 2021 using a combination of available cash resources and RCF drawings. Post this repayment the Group maintains significant liquidity but with a lower average cost of borrowing.

The Group's remaining debt facilities consist of a committed £105 million Revolving Credit Facility (RCF), which expires in 2023, and US$75 million of private placements expiring April 2024 (US$50 million) and 2026 (US$25 million).

Outlook

We are encouraged by the good volume growth performance in Q1 and, whilst we expect this trend to continue we remain mindful of the uncertainties arising from the ongoing COVID-19 pandemic and likely foreign exchange headwinds. As a result, our expectations for 2021 remain unchanged.

ENDS 

Contacts:

 

Devro plc

Rutger Helbing

Chief Executive Officer

Tel: 020 3865 7637

Rohan Cummings

Chief Financial Officer

Tel: 020 3865 7637

 

FTI Consulting

Richard Mountain

Nick Hasell

Tel: 020 3727 1340

 

Dividend: In the Company's announcement on 2 March 2021 of its results for the year ended 31 December 2020, the Board proposed a final dividend of 6.3p per share (the "2020 Final Dividend") to be paid on 1 October 2021, to those shareholders on the register at 20 August 2021, subject to shareholder approval at the Annual General Meeting in April 2021. The Board has subsequently resolved to recommend the payment of the 2020 Final Dividend be brought forward from 1 October 2021 to 20 July 2021, to those shareholders on the register at 11 June 2021.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSEFFWAEFSEDL
Date   Source Headline
7th Apr 20204:00 pmRNS2019 Annual Report and Notice of AGM
31st Mar 202012:03 pmRNSPrice Monitoring Extension
26th Mar 20204:37 pmRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSDirectorate Changes
9th Mar 20202:26 pmRNSHolding(s) in Company
6th Mar 20205:10 pmRNSDirector/PDMR Shareholding
6th Mar 202012:11 pmRNSDirector/PDMR Shareholding
6th Mar 202012:11 pmRNSDirector/PDMR Shareholding
4th Mar 20207:00 amRNSFull Year Results
17th Jan 20207:00 amRNSTrading Update
12th Dec 20198:42 amRNSDirector Declaration
25th Oct 20195:31 pmRNSDirector/PDMR Shareholding
24th Oct 201910:57 amRNSDirector/PDMR Shareholding
22nd Oct 20197:00 amRNSTrading Update & Manufacturing Footprint Review
10th Oct 201911:44 amRNSDirector/PDMR Shareholding
20th Sep 201912:59 pmRNSHolding(s) in Company
14th Aug 20191:45 pmRNSHolding(s) in Company
31st Jul 20197:00 amRNSHALF YEAR RESULTS
5th Jul 20191:17 pmRNSHolding(s) in Company
19th Jun 20197:00 amRNSHolding(s) in Company
15th May 20196:24 pmRNSDirector/PDMR Shareholding
14th May 20193:44 pmRNSDirector/PDMR Shareholding
7th May 20197:00 amRNSDirectorate Changes
2nd May 20193:28 pmRNSDirector/PDMR Shareholding
25th Apr 20194:04 pmRNSResult of AGM
25th Apr 20197:00 amRNSTrading Update
12th Apr 20191:08 pmRNSCompany Secretary change
11th Apr 201910:48 amRNSDirector/PDMR Shareholding
22nd Mar 20194:07 pmRNS2018 Annual Report and Notice of AGM
19th Mar 20192:00 pmRNSCapital Markets Event
6th Mar 20192:09 pmRNSDirector/PDMR Shareholding
6th Mar 20192:08 pmRNSDirector/PDMR Shareholding
26th Feb 20197:00 amRNSFull Year Results
20th Feb 20193:27 pmRNSHolding(s) in Company
14th Feb 201911:59 amRNSHolding(s) in Company
14th Feb 201911:34 amRNSDirector/PDMR Shareholding
23rd Jan 20193:02 pmRNSHolding(s) in Company
10th Dec 20184:05 pmRNSHolding(s) in Company
4th Dec 20184:46 pmRNSHolding(s) in Company
20th Nov 20183:33 pmRNSHolding(s) in Company
20th Nov 201811:51 amRNSHolding(s) in Company
19th Nov 20181:35 pmRNSDirector/PDMR Shareholding
19th Nov 20181:34 pmRNSDirector/PDMR Shareholding
16th Nov 201810:33 amRNSDirector/PDMR Shareholding
15th Nov 20187:00 amRNSRetirement of Chairman
15th Nov 20187:00 amRNSTrading Update
5th Nov 20181:49 pmRNSHolding(s) in Company
23rd Oct 20183:47 pmRNSHolding(s) in Company
15th Oct 20184:27 pmRNSDirector/PDMR Shareholding
18th Sep 201811:33 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.